4.7 Article

Impact of inappropriate empirical therapy for sepsis due to health care-associated methicillin-resistant Staphylococcus aureus

Journal

JOURNAL OF INFECTION
Volume 58, Issue 2, Pages 131-137

Publisher

W B SAUNDERS CO LTD
DOI: 10.1016/j.jinf.2008.11.003

Keywords

Methicillin-resistant Staphylococcus aureus; Cross-infections; Health care-associated infections; Outcome; Mortality; Multicenter study

Funding

  1. Ministerio de Sanidad y Consumo
  2. Instituto de Salud Carlos III - FEDER
  3. Spanish Network for the Research in Infectious Diseases [REIPI C03/14, REIPI RD06/0008]

Ask authors/readers for more resources

Objectives: We investigated the influence of empirical therapy on the mortality of patients with health care-associated (HCA) sepsis caused by methicillin-resistant Staphylococcus aureus (MRSA) infections in a multicenter cohort, and the variables associated with inappropriate empirical therapy. Methods: All new cases of infection caused by HCA-MRSA presenting with sepsis syndrome in 59 Spanish hospitals during June 2003 were prospectively followed. The main outcome variable was mortality at day 30. Predictors of mortality and of inappropriate empirical therapy were studied using multivariate logistic regression. Results: We included 209 cases. Crude mortality was 23%. After controlling for severity of the underlying condition, ICU stay, presentation with severe sepsis or shock, and site of infection, inappropriate empirical therapy was associated with an increased odds of mortality (OR = 3.0; 95% Cl: 1.01-9.0; p = 0.04). Only 21.1% of the patients received appropriate empirical therapy. Variables independently associated with appropriate therapy were recent surgery, central venous catheter and certain sites of infection (primary bacteraemia, intraabdominal infections, and respiratory tract infections). Cancer patients were at an increased risk of receiving inappropriate therapy. Conclusions: Inappropriate empirical therapy was independently associated with increased mortality in this multicenter cohort. Clinicians should be aware of the need to consider coverage against MRSA more frequently. (C) 2008 The British Infection Society. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available